Leadership

Elizabeth Elting

Co-Founder
TransPerfect

Liz Elting co-founded TransPerfect in 1992. Today, TransPerfect is the world’s largest privately held provider of language and business solutions. Headquartered in New York City, the company has more than 3,500 employees and over 90 offices in cities around the globe. Elting has earned numerous awards for her outstanding entrepreneurship and focus on developing women business leaders. They include: the Working Woman “Entrepreneurial Excellence” Award for Customer Service, the Ernst and Young “Entrepreneur of the Year” Award, the American Express-Entrepreneur Magazine “Woman of the Year” Award, the "Distinguished Alumnae" Award from NYU Stern's Women in Business, the “Women Worth Watching” Award from Diversity Journal, and most recently, the "Women of Power & Influence" Awards by the National Organization for Women.

Elting is profiled in several books, including "American Dream: Interviews with Industry-Leading Professionals" by Jason Navallo, The New York Times bestseller “Succeed by Your Own Terms” (McGraw-Hill), “Leadership Secrets of the World’s Most Successful CEOs” (Dearborn Trade Publishing), and “Straight Talk About Starting and Growing Your Business” (McGraw-Hill). She is featured regularly in the media, including The New York Times, The Wall Street Journal, Forbes, O (The Oprah Magazine), The Financial Times, Reader’s Digest, Huffington Post, and Crain’s New York Business.

With Elting’s commitment and vision, TransPerfect has been an eight-time recipient of the Inc. 5000 Award, a six-time honoree of the Deloitte Technology Fast 500, and has earned multiple Stevie Awards, including “Company of the Year” and “Fastest Growing Tech Company of the Year” in 2016. Crain’s New York Business has named TransPerfect one of the largest privately held companies for 11 consecutive years, and one of the largest women-owned companies ten times. The company was a winner of the 2015 SmartCEO Corporate Culture Awards, and named the Internet Marketing Association’s “Best Translation Solution” at the IMPACT15 Conference. TransPerfect has also been named one of the fastest-growing women-owned/led businesses in North America by Entrepreneur and the Women Presidents' Organization.

Elting serves on the Trinity College Board of Trustees, and is a regular speaker at both NYU and Columbia Business Schools. She is the Founding Ambassador for the American Heart Association's Circle of Red, an Enterprising Women Advisory board member, and a member of the Women Presidents' Organization's Zenith Group.

Elting holds an MBA in Finance and International Business from The Stern School of Business at New York University and a BA in Modern Languages and Literatures from Trinity College in Hartford, CT.

Phil Shawe

Co-Founder
TransPerfect

Phil Shawe is the co-founder of one of the world's leading B-to-B providers of language and business services, TransPerfect Global, and is the President and CEO of Translations.com. From 1992 until 1999, Shawe co-managed the day-to-day operations of TransPerfect with his business partner, Elizabeth Elting, to help orchestrate the company's growth from a single office start-up to an industry leader, operating from offices in over 85 cities on six continents. Prior to founding TransPerfect, Shawe was a Financial Analyst at Chemical Bank and a Global Custody Consultant at Merrill Lynch. Shawe holds an MBA from NYU's Stern School of Business and a BS from the University of Florida where he triple majored in Finance, Marketing, and Risk Management.

Michael Smyth

General Manager, Life Sciences Solutions
Trial Interactive

Michael Smyth is the General Manager of TransPerfect's Life Science Solutions division, including the Trial Interactive platform and its solutions. Smyth has over 20 years of experience working in the pharmaceutical clinical development industry. Prior experience includes clinical and vaccine development at Teva Pharmaceuticals, Merck, Quintiles, and Premier Research managing large global phase III international trials that have resulted in the approval of products including Daytrana and Focalin for ADHD, Copaxone for Multiple Sclerosis, and others. He has also spent over five years in clinical technology and services solutions supporting life sciences companies on a global basis with a strategic goal to move towards a paperless clinical development environment. Michael consults with our pharmaceutical, biotechnology, medical device, and CRO clients to determine how to most efficiently use our Trial Interactive platform to streamline clinical development processes for all stakeholders. Smyth is an active member of the Drug Information Association as well as several clinical technology forums and has spoken at industry conferences on the multicultural challenges and solutions in conducting global clinical trials.